Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Facing the future: “How can a 3-year old understand that her... January 12, 2022 Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer July 1, 2021 FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... May 26, 2025 Load more HOT NEWS FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... FDA Approves Second CAR T-Cell Therapy for Lymphoma Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body...
